TürkiyeSGK and reimbursement
A third SMA drug to be added to the reimbursement list, minister announces
A statement by a ministry, institution or international organisation, or a change in regulations. It is not evidence about how well a treatment works.
Another drug used to treat children with SMA will be added to the SGK (Social Security Institution) reimbursement list. This was announced by Minister of Labor and Social Security Vedat Işıkhan. Nusinersen was already covered by reimbursement. The gene therapy onasemnogene abeparvovec for type 1 SMA was also covered. The new drug was said to be easier to use.
What does it mean for patients and families?
Once the coverage takes effect, families of children with SMA can ask their SMA center: is the new option suitable for their child?
Source
Yeni Şafak: Bakan Işıkhan duyurdu: SMA tedavisinde yeni ilaç SGK geri ödeme listesine dahil edilecek
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Spinal muscular atrophy (SMA)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.